AC Immune SA ACIU 深 沪
等待开盘 04-01 09:30:00 美东时间
2.75
+0.190
+7.42%
华盛通- 最 高2.77
- 今 开2.61
- 成交量 12.76万股
- 最 低 2.59
- 昨 收 2.56
- 总市值 2.77亿
- 52周最高 4.00
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 1.45
- 委 比 -61.39%
- 总股本 1.01亿
- 历史最高 17.40
- 量 比 0.68
- 振 幅 7.03%
- 历史最低 1.4299
- 每 手 1
- 风险率 0.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed
BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 19 (Reuters) - Wall Street's main indexes were set to open lower on
03-19 21:15
BUZZ-U.S. STOCKS ON THE MOVE-Alibaba, Accenture, energy companies
BUZZ-U.S. STOCKS ON THE MOVE-Alibaba, Accenture, energy companies Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 19 (Reuters) - U.S. stock index futures slipped on Thursda
03-19 20:05
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.
03-16 18:24
AC Immune Q4 EPS $(0.17) Beats $(0.19) Estimate, Sales $422.914K
AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 7.89 percent. This is a 2.78 percent increase over losses of $(0.18) per share from the same
03-13 19:12
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
AC Immune will host an industry symposium on precision prevention for Parkinson’s disease on March 18, 2026, featuring expert discussions on targeting α-synuclein and clinical advancements. The company will also present its first-in-class TDP-43 PET-tracer ACI-19626 at AD/PD 2026 in Copenhagen, highlighting its potential in neurodegenerative disease diagnostics.
03-05 12:00
BRIEF-Ac Immune Says Informed Enrollment Has Been Temporarily Paused For Phase 2B Retain Trial
BRIEF-Ac Immune Says Informed Enrollment Has Been Temporarily Paused For Phase 2B Retain Trial Feb 17 (Reuters) - AC Immune SA ACIU.O : AC IMMUNE SA: INFORMED BY JANSSEN PHARMACEUTICALS THAT ENROLLMENT HAS BEEN TEMPORARILY PAUSED FOR PHASE 2B RETAIN TRIAL AC IMMUNE SA: TEMPORARY PAUSE IN PHASE 2B RE
02-18 05:49
美股牛股 | SMX飙升45%，公司在棉花可追溯性方面获重大突破；PL大涨35%
SMX飙升45%，公司在棉花可追溯性方面获重大突破；PL大涨35%，财报收入大增超预期；GEMI大涨32%，公司获合约市场牌照进军预测市场>>
2025-12-12 16:17
BUZZ-U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond Hill
Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures tumbled o...
2025-12-11 22:39
AC Immune Announces Interim Safety And Efficacy Results From Phase 2 VacSYn Trial Of Its Wholly-Owned Anti-Alpha-Synuclein Active Immunotherapy ACI-7104.056 In Early Parkinson's Disease
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced positive interim safety and efficacy results from the Phase 2
2025-12-11 20:02
